Advancis’ Last Try For Pulsys Platform? New Phase III Trial To Start In November
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Advancis is prepared to begin a new Phase III trial of its Pulsys pulsatile amoxicillin formulation in November in hopes of following through with its previously planned NDA